James Parsons
Director/Board Member chez DIAMEDICA THERAPEUTICS INC.
Fortune : 277 626 $ au 31/03/2024
Profil
James T.
Parsons is currently the Director at Oncolytics Biotech, Inc. and the Independent Director at Sernova Corp.
He also serves as the Independent Director at DiaMedica Therapeutics, Inc. In the past, Mr. Parsons held positions as the Director at YM BioSciences, Inc., Vice President-Finance & Administration at Aptose Biosciences, Inc., Controller & Assistant Treasurer at Timminco Ltd., Chief Financial & Accounting Officer at Trillium Therapeutics ULC, Chief Financial Officer at ProMIS Neurosciences, Inc., and Chief Financial Officer & Secretary at Trillium Therapeutics, Inc.Mr. Parsons obtained a graduate degree from The University of Waterloo.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SERNOVA CORP.
0,09% | 25/04/2023 | 284 728 ( 0,09% ) | 117 023 $ | 31/03/2024 |
| 01/06/2022 | 38 509 ( inf% ) | 106 670 $ | 31/03/2024 | |
ONCOLYTICS BIOTECH INC.
0,06% | 07/03/2024 | 45 000 ( 0,06% ) | 47 700 $ | 31/03/2024 |
| 25/03/2024 | 2 250 ( 0,01% ) | 6 233 $ | 31/03/2024 |
Postes actifs de James Parsons
| Sociétés | Poste | Début |
|---|---|---|
| DIAMEDICA THERAPEUTICS INC. | Director/Board Member | 01/10/2015 |
| SERNOVA CORP. | Director/Board Member | 19/04/2012 |
| ONCOLYTICS BIOTECH INC. | Director/Board Member | 16/06/2022 |
Anciens postes connus de James Parsons
| Sociétés | Poste | Fin |
|---|---|---|
| TRILLIUM THERAPEUTICS | Director of Finance/CFO | 17/11/2021 |
Trillium Therapeutics, Inc. /Old/
 Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Director of Finance/CFO | 06/06/2014 |
| PROMIS NEUROSCIENCES, INC. | Director of Finance/CFO | 20/10/2010 |
| APTOSE BIOSCIENCES INC. | Director of Finance/CFO | 01/01/2003 |
| TIMMINCO LIMITED | Comptroller/Controller/Auditor | 01/01/2000 |
Formation de James Parsons
| The University of Waterloo | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| APTOSE BIOSCIENCES INC. | Health Technology |
| ONCOLYTICS BIOTECH INC. | Health Technology |
| SERNOVA CORP. | Health Technology |
| TIMMINCO LIMITED | Producer Manufacturing |
| DIAMEDICA THERAPEUTICS INC. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
